Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 129 Carcinoma, Non-Small-Cell Lung 101 Prostatic Neoplasms 62 Colorectal Neoplasms 48 Nasopharyngeal Carcinoma 45 Neoplasms 44 Multiple Myeloma 41 Stomach Neoplasms 35 Leukemia, Myeloid, Acute 32 Ovarian Neoplasms 31 Neoplasm Metastasis 31 Lung Neoplasms 31 Carcinoma, Hepatocellular 29 Squamous Cell Carcinoma of Head and Neck 27 Rectal Neoplasms 27 Pancreatic Neoplasms 26 Triple Negative Breast Neoplasms 25 Recurrence 25 Small Cell Lung Carcinoma 21 Brain Neoplasms 21 Esophageal Neoplasms 20 Colonic Neoplasms 20 Uterine Cervical Neoplasms 19 Lymphoma, Large B-Cell, Diffuse 17 Head and Neck Neoplasms 17 Urinary Bladder Neoplasms 16 Leukemia, Lymphocytic, Chronic, B-Cell 16 Esophageal Squamous Cell Carcinoma 16 Carcinoma, Renal Cell 16 Myasthenia Gravis 15

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recruiting × GIST × Clear all

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡